Pseudohypoparathyroidism type II and anticonvulsant rickets.
A patient treated with anticonvulsants showed hypocalcemia and hyperphosphatemia in association with increased serum parathyroid hormone, reduced serum 25-hydroxy D3, diminished response in phosphorus excretion to exogenous parathyroid hormone and normal response in cyclic AMP excretion. Oral administration of Vitamin D3 resulted in normalization of serum 25-hydroxy D3, calcium, and phosphorus. At this stage, phosphorus excretion after parathyroid hormone returned to normal. These findings suggest that the patient had pseudohypoparathyroidism type II with anti-convulsant medication as a complicating factor.
D000293:Adolescent; D000927:Anticonvulsants / Q000009:adverse effects*; D002762:Cholecalciferol / Q000627:therapeutic use; D006801:Humans; D008297:Male; D011547:Pseudohypoparathyroidism / Q000150:complications*; D012279:Rickets / Q000139:chemically induced / Q000150:complications* / Q000188:drug therapy
D000927:Anticonvulsants; D002762:Cholecalciferol